MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.
Our mission is to advance medicines that will provide a brighter future for patients with serious conditions that are not fully served by existing treatments.
The Biodexa Pharmaceuticals team benefits from cross-functional expertise including formulation science and pharmaceutical development. With over 10 years’ experience of working together the team has translated multiple programmes from concept to clinic across three distinct technology platforms and apply extensive knowledge and expertise to deliver rapid R&D innovation and value creation.
CEO / CFO
Chief Scientific Officer
Group Financial Controller
VP Business Development
VP Head of Clinical Operations
Board of Directors
CEO / CFO
Senior Independent Non-executive Director
Sijmen de Vries